Education
About Us
Working with TipRanks
Follow Us
Inmune Bio Inc (INMB)
NASDAQ:INMB
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.48Last Year’s EPS
-0.61Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: 0.81%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant upcoming milestones, such as the anticipated Phase 2 trial results for Alzheimer's and the BLA filing for the CORDStrom program. However, the increased net loss and high patient screening failure rate were notable challenges. Despite these challenges, the company's fundraising efforts have provided sufficient financial stability to continue operations.Company Guidance
During INmune Bio's 2024 fourth quarter and full-year earnings call, several key metrics and guidance were provided. The company is on track to announce top-line data in less than 100 days for its Phase 2 trial of XPro in treating early Alzheimer's disease (AD) with inflammation, enrolling 208 patients across eight countries. This trial employs a precision medicine approach, using EMACC as the primary endpoint to assess cognitive function. The trial has a 72% screen failure rate, consistent with other AD trials. Financially, INmune Bio raised $29.9 million through common stock and warrants sales, with potential for an additional $30 million if warrants are exercised. The company reported a net loss of $42.1 million for 2024, with R&D expenses at $33.2 million. Cash and equivalents stood at $20.9 million at year-end, with an additional $5.4 million raised subsequently. The upcoming milestones include completing the metastatic castration-resistant prostate cancer program and filing a BLA for CORDStrom in Q1 2025.Upcoming Phase 2 Trial Results for Alzheimer's
In less than 100 days, INmune Bio will announce top-line data for their Phase 2 trial using XPro to treat early Alzheimer's disease focusing on neuroinflammation. This trial stands out due to its use of biomarkers for patient selection and the novel endpoint EMACC to assess cognitive function.
CORDStrom Program for RDEB
The CORDStrom program is ready for a BLA filing and has been awarded orphan drug status and rare pediatric disease designation. It provides a systemic, disease-modifying approach for treating RDEB, and preparation for the BLA submission is underway.
Financial Stability and Fundraising
INmune Bio raised $29.9 million from the sale of common stock and warrants, with the potential to raise an additional $30 million. The company has cash and cash equivalents of approximately $20.9 million, sufficient to fund operations through Q3 2025.
---
INMB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INMB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $7.41 | $7.52 | +1.48% |
| Oct 31, 2024 | $5.85 | $6.04 | +3.25% |
| Aug 01, 2024 | $7.91 | $8.17 | +3.29% |
| May 09, 2024 | $10.77 | $10.02 | -6.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Inmune Bio Inc (INMB) report earnings?
Inmune Bio Inc (INMB) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Inmune Bio Inc (INMB) earnings time?
Inmune Bio Inc (INMB) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INMB EPS forecast?
INMB EPS forecast for the fiscal quarter 2025 (Q1) is -0.48.
---